aTyr Pharma (LIFE) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
May 9, 2022 4:00 PM EDTCompany to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May.
Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022.
FDA granted orphan drug designation for efzofitimod for the treatment of systemic sclerosis; company to explore potential expansion of clinical program in other ILD.
Ended the first quarter 2022 with $98.7 million in cash, cash equivalents and investments.
Company to host... More
